How Myers was paid
$1.5M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Dr. Michael MyersChief Executive Officer | $745,284 | — | $331,285 | $372,642 | $58,134 | $1,507,345 |
| Denise CarterChief Operating Officer | $595,440 | — | $331,285 | $297,720 | $57,840 | $1,282,285 |
| Sally LawlorChief Financial Officer | $165,206 | $83,134 | $174,784 | — | $11,168 | $434,292 |
What changed and why
- $1.5M$1,507,345 was Dr. Myers’ total compensation, up from $1,406,801 in 2024.
- $745K$745,284 was Dr. Myers’ 2025 salary, retroactive to January 1, 2025.
- 100%$372,642 was Dr. Myers’ performance-based cash bonus after achievement of 100% of performance goals.
- $331K$331,285 was the grant-date value of options awarded to each of Dr. Myers and Ms. Carter.
- August 18, 2025 marked Sally Lawlor’s appointment as Chief Financial Officer.
- $83,134$83,134 was Ms. Lawlor’s discretionary cash bonus for 2025 services.
Other Quoin Pharmaceuticals proxy statements
- 2025 proxy statement
Dr. Michael Myers paid $1.4M (+12% on the year).
Filed Jul 17, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.